Stockrabit · Analysts
Questions across 17 calls

Surya Patra

Firm not listed in source transcripts

Biocon Limited

Biocon Limited CC-May26.pdf · 2026-05-08
This is Surya from Phillip Capital. A couple of questions. First, with the ramp-up that we are likely to see in the biosimilar portfolio, although we have started seeing strong growth in the U.S. business front given the kind of products that has been launched during FY '26 and the products like the Eylea that is there along with denosumab contribution in the current financial year. So , what is the kind of momentum that we would see for the U.S. business? And what is the likely share of U.S. business in FY '27 versus FY '26? Because basically, what we are seeing that, okay, so far, it is the non -U.S. would have supported the growth meaningfully. But now there is a strong lever for the U.S. to perform and really contribute meaningfully to the margins also. So how the mix likely to see the shift.
Sir, any clarity on the exclusivity that it could have for Eylea now?
Biocon Limited CC-Nov25.pdf · 2025-11-12
Thank you for the opportunity and congratulations for the great set of numbers. My first question is about the generic business. So obviously, we have seen a strong ramp up there. But now is it possible to share, sir, what is the split between the formulat ion and API business right now? And, if you can talk a bit more about the margin profile, which has been relatively low currently given the kind of historical margin profile trend what we have been having, even though we have been having that on the API business at the time?
Got you. Extended point on the GLP capability and all that. We know that Biocon is one of the very limited players having the end -to-end manufacturing capability, starting from the drug substance to device to fill finish and all that. So since now this Semaglutide filing, the Liraglutide opportunity fill finish, all those are kind of in the visible range. So, could you share some idea that, okay, what is the device capacity that we would be having, what is the fill finish capacity that we would be having or in a different term, like what device capacity or what vial capacity that we are working with right now?

Lupin Limited

Lupin Limited CC-Nov25.pdf · 2025-11-07
My first question is on the India business, you have mentioned that excluding for the LOEs, the growth is really strong, better than the industry trend. So when would we start seeing the normalized growth momentum or exclusive of the kind of impact what that has been there so far?
And in the meanwhile, I think the growth of the industry itself has muted. So, do you think that is having some impact to the overall industry growth trend in the domestic market and hence your growth may not be double -digit? Anything of that sort?

Zydus Lifesciences Limited

Zydus Lifesciences Limited CC-Mar25.pdf · 2025-05-20
Thank you for the opportunity . Sir, my first question is on the US business again. Sir , although you have given some clarity about the change of around 80 million dol lar this quarter versus last quarter what we have seen . See, if there is no Revlimid this quarter and there is a jump of 80 million do llar, what is that is contributing? Is it driven by Mirabegron or there is a kind of any licensing income or anything is there this quarter that is why we are seeing a kind of consequent improvement in the gross margin? What is really driving this US business this quarter? Is there any one-off kind of licensing income or any sort of that? Can you justify please?
Sir, few of your peers have already indicated that Revlimid has already started seeing some kind of price erosion in the US. So, given that , do you agree to that fact and this is likely to be the 12 of 22 scenario going ahead till the time of this entire opportunity expiry?
Zydus Lifesciences Limited CC-Mar24.pdf · 2024-05-17
Yeah, thanks for this opportunity Sir and congrats for the strong set of numbers. Sir, my first question is on the margin improvement sequentially w hat we have seen . I f I just adjust for let's say some Revlimid kind of a number out of the total reported, it looks like that your base business has seen t he gross margin which is highest ever. And if this is the case, back to back , even third quarter gross margins were significantly better for the base business adjusted for Revlimid. So, what is driving this ? Or it is largely to do with the cons umer business doing better than expected?
So, in that case, so what is the sustainable, means whether this is a sustainable one or we can grow up on this ? That is one. And , secondly, the spike in the other expenses also what we are witnessing in this quarter . Is it also largely led by the cons umer business contributing significantly? 11 of 23
Zydus Lifesciences Limited CC-Dec23.pdf · 2024-02-09
Yeah. Thank you for this opportunity, Sir. And congrats for the great set of numbers. My first question is on the gross margin front. So, while we know that the elevated number of gross margin number that we have seen in the recent quarters, it was obviously initially aided by the launch of Revlimid. But in the last two quarters, without Revlimid, we have been almost maintaining the similar kind of gross margin. So , here what is driving this? And it looks like that without Revlimid, if you are maintaining this, then subsequent quarter with Revlimid, we can see even improved number and whether this kind of run rate is sustainable? 10 of 18
Okay. So just an extended one. Even for the current year, you have guided that EBITDA margin would be around 27%. So, I think this is a kind of a great number that we are achieving after a gap. So, given the kind of a potential annual volume ramp up that you will see in Revlimid in the subsequent financial year and again, product mix, both in the US as well as in the India market, seeing a kin d of improvement. So, are you kind of guiding a more than 27% kind of margin run rate for next year?

Aarti Industries Limited

Aurobindo Pharma Limited

Aurobindo Pharma Limited CC-Sep23.pdf · 2023-11-10
Hello. Yeah, thank you, sir. Congratulations for the great set of numbers and their broad-based performance across segments and across line items. My first question is on the strong double-digit growth, what we are witnessing in the US oral solid business. Whether this is a kind of temporary momentum, as you mentioned that you are witnessing volume growth as well as new product launches and all that. But is it a temporary momentum that you are witnessing, or it is kind of a sustainable run rate that we are now having? And can we maintain near double-digit growth consistently in the near future for the oral solid business , Sir?
Okay. Okay. Thank you, Sir. And secondly, on the injectable front, basically the gRevlimid. Sir, you have launched the gRevlimid this quarter. But any sense whether our volume share are likely to be kind of average of the existing players? And the pricings are similar to the existing players? I mean, some sense if you can give?
Aurobindo Pharma Limited CC-Mar25.pdf ·
Yeah, thanks for the opportunity, sir, and good set of numbers. Congrats for the good set of numbers, basically. My first point is, in the opening remarks, you mentioned that the growth is likely to be sustained in FY26. But you highlighted about the growth obviously would be led by the Europe and emerging market s, but kind of remained silent about the other bigger markets like US and all. So, knowing the fact that US contributes almost like 45% of the total. So, is there a kind of a risk that we have to the overall growth guidance? Or if you can give clarity more on the US business?
Okay, okay, fine. Regards the European business , it looked like that it has surpassed your earlier guidance of €900 odd billion. And now, optically, there are things which should contribute incrementally to the growth. And you have also mentioned about the possibility or what are the factors of growth here. I just wanted to have a sense that, regards the kind of facilities that would be contributing towards the growth. So, obviously, we have been saying that the China plant which has commissioned, that will facilitate the growth in Europe. The Vizag facility is also likely to see the injectable growth in Europe. So, on that specific front, sir, supply chain for Europe, if you can be a bit more elaborative about what progress you have already achieved, so far as your injectable launches for Eu rope? And how meaningful the China supply could be for Europe ? Because last year, I believe still the outsourcing of European operation was still to the tune of around 50 odd percentage. So, going ahead for FY26, given these two plans progress, what one should think and expect?
Aurobindo Pharma Limited CC-Dec24.pdf ·
Thanks for the opportunity, Sir. My first question is on the respiratory product opportunity. What you have talked in the opening remarks also, so we know that there has been around 14 odd products that has already been there in the various stages of development, and I think the last quarter that we have also collaborated with one of the U.S. company to develop even a basket more. So, could you give some sense of what is the progress on those products? What kind of product that we are talki ng about there , and by when that we will really start seeing revenue contribution coming from that side?
Okay. And this collaboration, if you can just add some color on this?
Aurobindo Pharma Limited CC-Dec23.pdf ·
Hello. Thanks for this opportunity, Sir. My first question is on the same question as the previous question basically, the in -licensed molecule. So, you indicated that second half of the current calendar year that you will be launching, but which are the markets that you are initially talking about. And do you see this as a kind of exact a lternative of P EG- filgrastim?
Okay. So, considering the potential or the size of Pegfilgrastim, this could be one of the largest product opportunity for near term is that…

Sun Pharmaceutical Industries Limited

Sun Pharmaceutical Industries Limited CC-May26.pdf ·
Yes, thank you. Thanks for this opportunity and congratulations for the great transaction, sir. My first question is on the R&D capabilities that we are having from Organon. So what is the nature of R&D that they are currently having because we know that the roots of R&D with Organon comes from Merck. So here whether it is a branded, generic kind of R&D capability or it is the innovative R&D capability and is there any scope for rationalization of the R&D spend there?
Sure, sir. Second question is on the synergy that we have mentioned, whatever $350 million flowing largely from cost side. On the revenue side are we considering that we can best in the near term maintain the revenues what what Organon is currently generating or any reason that we are not highlighting the scope of any synergy benefit flowing from the revenue side and what is the scope of this cross -selling opportunities that we can have? So if you can talk little bit on that front?